Alectinib eclipses crizotinib for ALK positive lung cancer

Results from the APHINITY trial of two HER2 targeted agents with chemo

Treating BRCA breast cancer with PARP inhibition

Relieving spinal cord compression symptoms with a single radiation treatment

Halving duration of ADT for high risk prostate cancer patients

Nivolumab and ipilimumab for metastatic sarcoma

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Phase III results of olaparib for BRCA breast cancer

Global health initiative oncology

Tivantinib as second line therapy for high-MET HCC

Olaparib slows growth of BRCA-related metastatic breast cancer

3 or 6 months adjuvant oxaliplatin for colorectal cancer